Company Filing History:

10 out of 932

University of British Columbia

patents

2 out of 505

Teva Pharmaceutical Industries Limited

patents

Years Active: 2005-2015

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9095602 - Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides (2015-08-04),

2. 9074209 - TRPM-2 antisense therapy (2015-07-07),

3. 8536149 - TRPM-2 antisense therapy (2013-09-17),

4. 8361981 - Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides (2013-01-29),

5. 8173615 - TRPM-2 antisense therapy (2012-05-08),

6. 7732422 - TRPM-2 antisense therapy (2010-06-08),

7. 7592323 - TRPM-2 antisense therapy (2009-09-22),

8. 7534773 - TRPM-2 antisense therapy (2009-05-19),

9. 7491816 - Antisense therapy for hormone-regulated tumors (2009-02-17),

10. 7368436 - TRPM-2 antisense therapy (2008-05-06),

11. 7297684 - Antisense therapy for hormone-regulated tumors (2007-11-20),

12. 6900187 - TRPM-2 antisense therapy using an oligonucleotide having 2'-O-(2-methoxy)ethyl modifications (2005-05-31),

Title: Innovations in Cancer Treatment by Inventor Hideaki Miyake

Introduction

Hideaki Miyake is a prominent inventor based in Vancouver, Canada, known for his significant contributions to cancer treatment. With a total of 12 patents, he has focused on developing innovative methods to enhance the effectiveness of chemotherapy and radiation therapy for cancer patients.

Latest Patents

Miyake's latest patents include groundbreaking work on chemo- and radiation-sensitization of cancer through antisense TRPM-2 oligodeoxynucleotides. This method involves administering antisense oligodeoxynucleotides targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene. By reducing the amount of TRPM-2 in renal cell cancer (RCC) cells, this approach enhances the sensitivity of these cells to chemotherapy agents and radiation. Consequently, renal cell cancer cells can be treated more effectively, overcoming their general resistance to known chemotherapy agents.

Another notable patent is the TRPM-2 antisense therapy, which outlines a method for treating individuals suffering from cancer. This method involves administering a chemotherapeutic agent alongside an antisense oligonucleotide that has a phosphorothioate modification, increasing its stability in vivo. This innovative approach targets cancers that express TRPM-2, providing a new avenue for treatment.

Career Highlights

Miyake has had a distinguished career, working with esteemed organizations such as the

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

1 patent pending (CIPO):

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.